MRK - Merck & Co., Inc.

NYSE - Nasdaq Real Time Price. Currency in USD
70.64
+0.66 (+0.95%)
As of 11:13AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close69.98
Open70.35
Bid70.50 x 900
Ask70.51 x 800
Day's Range70.05 - 70.65
52 Week Range52.83 - 70.94
Volume1,536,371
Avg. Volume8,269,015
Market Cap187.882B
Beta1.06
PE Ratio (TTM)145.66
EPS (TTM)0.49
Earnings DateOct 25, 2018
Forward Dividend & Yield1.92 (2.74%)
Ex-Dividend Date2018-09-14
1y Target Est72.88
Trade prices are not sourced from all markets
  • Pharma Stocks: GlaxoSmithKline’s Revenue Trend and 2018 Estimates
    Market Realist44 minutes ago

    Pharma Stocks: GlaxoSmithKline’s Revenue Trend and 2018 Estimates

    GlaxoSmithKline reported a nearly flat top line at 7.3 billion pounds, including a 4% rise in operating revenue offset by a 4% negative foreign exchange impact. GlaxoSmithKline’s business is divided into three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare.

  • MarketWatch3 hours ago

    Galectin stock lifts 15% premarket on early cancer combination trial results

    Galectin Therapeutics Inc. shares surged 15% in Thursday premarket trade after the company said that combining its therapy, GR-MD-02, with Keytruda, Merck & Co.'s leading cancer therapy, appeared to have better results for patients with advanced melanoma than Keytruda alone. Notably, though, results were preliminary, based on data from an early-stage, phase 1b clinical trial, and integrated results from two earlier groups of patients on lower doses of GR-MD-02 with a third, higher-dose group. Galectin said that of 14 patients across the three groups, seven had reductions in cancer tumor size, or an objective response rate of 50%. Meanwhile, Keytruda alone has response rate that ranges between 21% to 39%, noted Dr. Brendan Curti, the trial's principal investigator and the director of the Providence Cancer Institute's melanoma program. Of the trial's 14 patients, nine had their cancer improve or remain stable, or a disease control rate of 64%. The phase 1b trial also enrolled six patients with head and neck cancer, for whom a 33% objective response rate and 67% disease control rate were observed. Curti said he and others were "very encouraged" by the melanoma results, and noted that results in both cancers were better than expected for Keytruda on its own. The trial will move forward in both areas, he said, and they plan to include more patients. Galectin shares have dropped nearly 24% over the last three months, compared with a 5.1% rise in the S&P 500 and a 7.1% rise in the Dow Jones Industrial Average .

  • Merck Publishes Corporate Responsibility Report
    PR Newswire3 hours ago

    Merck Publishes Corporate Responsibility Report

    KENILWORTH, N.J., Sept. 20, 2018 /PRNewswire/ -- Merck (MRK), known as MSD outside the United States and Canada, today issued its 2017/2018 global Corporate Responsibility Report. "Our company has an important role to play in tackling some of humanity's greatest challenges," said Kenneth C. Frazier, chairman and chief executive officer, Merck. The report highlights Merck's approach to creating social, environmental and economic value for the company and its stakeholders and the company's commitment to operate ethically and transparently.

  • How Accenture’s Partnership with Merck Could Be Helpful
    Market Realist4 hours ago

    How Accenture’s Partnership with Merck Could Be Helpful

    Accenture (ACN) has teamed up with Merck & Co. (MRK), one of the leading pharmaceutical giants outside the United States, to drive production, effectiveness, and innovation in the initial stages of drug development. Both companies have included Amazon’s (AMZN) AWS (Amazon Web Services) cloud computing, The involvement of the leading public cloud service provider should allow MSD to introduce a cloud-based informatics research platform to support the life sciences industry related to drug manufacturing.

  • GuruFocus.com16 hours ago

    Merck & Co Inc (MRK) Chairman, President & CEO Kenneth C Frazier Sold $19. ...

    Chairman, President & CEO of Merck & Co Inc (NYSE:MRK) Kenneth C Frazier sold 279,851 shares of MRK on 09/18/2018 at an average price of $70.08 a share.

  • Can Accenture Meet Its Operating Margin Guidance in Q4 2018?
    Market Realistyesterday

    Can Accenture Meet Its Operating Margin Guidance in Q4 2018?

    Accenture (ACN) has forecast its operating margin for fiscal 2018 at 14.8%, which would be higher than its fiscal 2017 margin of 12.9%. In the past five quarters, it mostly sustained a double-digit operating margin. In the chart below, you can see its GAAP operating margin trend in the last five quarters.

  • Pharma Stocks in Review: A Valuation Comparison
    Market Realistyesterday

    Pharma Stocks in Review: A Valuation Comparison

    In this article, we’ll compare the valuations of Eli Lilly and Company (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK).

  • Accenture, Merck & Amazon AWS Partner for Cloud Platform
    Zacks2 days ago

    Accenture, Merck & Amazon AWS Partner for Cloud Platform

    Accenture's (ACN) latest partnership is likely to boost its Products segment.

  • MarketWatch2 days ago

    Health care ETF surges toward record in a broad sector rally

    The SPDR Health Care Select Sector ETF rose 0.7% toward a record high in afternoon trade Tuesday, with 55 of its 63 equity components gaining ground. Among the ETF's (XLV) members which are also Dow Jones Industrial Average components, Pfizer Inc.'s stock shot up 1.5%, putting it on track to close at the highest level since December 2001. Also, shares of Johnson & Johnson gained 0.6% toward an eight-month high, Merck & Co. Inc. tacked on 0.4% to sit just shy of its 17-year high reached last Thursday, and UnitedHealth Group Inc. slipped 0.1% and was 2.2% below its Sept. 6 record close of $269.65. The XLV's biggest gainer was Abiomed Inc.'s stock , which rallied 2.7%, while its biggest decliner was AbbVie Inc.'s stock , which shed 2.1% after California sued the company alleging the payment of illegal kickbacks. The XLV has rallied 11% over the past three months, while the Dow has tacked on 5.2%.

  • A Review of Pharma Stocks’ EPS Growth Rates
    Market Realist2 days ago

    A Review of Pharma Stocks’ EPS Growth Rates

    In this article, we’ll compare the EPS growth rates of pharmaceutical companies Eli Lilly and Company (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK).

  • Exploring Pharmaceutical Stocks’ Revenue Growth Rates
    Market Realist2 days ago

    Exploring Pharmaceutical Stocks’ Revenue Growth Rates

    In this article, we’ll compare the revenue growth rates of the pharmaceutical companies under review in this series: Eli Lilly and Company (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK).

  • Can Pfizer (PFE) Bank on Bavencio for Long-Term Growth?
    Zacks2 days ago

    Can Pfizer (PFE) Bank on Bavencio for Long-Term Growth?

    Pfizer's (PFE) latest anti-PD-L1 immunotherapy, Bavencio, is being touted as a significant long-term top-line driver for the company.

  • A Look at the Dividends Paid by Pharma Stocks in 2018
    Market Realist2 days ago

    A Look at the Dividends Paid by Pharma Stocks in 2018

    In this article, we’ll discuss the details of the dividends paid by pharmaceutical stocks Eli Lilly and Company (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK).

  • Delstrigo, Pifeltro, and Merck’s Antiviral Therapy Portfolio
    Market Realist2 days ago

    Delstrigo, Pifeltro, and Merck’s Antiviral Therapy Portfolio

    In the second quarter, Merck’s (MRK) Zepatier and Isentress reported revenues of $113.0 million and $305.0 million, respectively, which represented an ~78.0% decline and 8.0% growth on a YoY (year-over-year) basis. In the first half, Zepatier and Isentress reported net revenues of $243.0 million and $586.0 million, respectively.

  • A Look at the Market Caps of the Pharma Stocks under Review
    Market Realist3 days ago

    A Look at the Market Caps of the Pharma Stocks under Review

    As we discussed earlier, a few of the pharmaceutical stocks that have surpassed the returns of the S&P 500 Index YTD (year-to-date) include Eli Lilly and Company (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK). Let’s take a look at the details of their market caps.

  • How Pharmaceutical ETFs Have Performed in 2018
    Market Realist3 days ago

    How Pharmaceutical ETFs Have Performed in 2018

    Pharmaceutical ETFs are securities that are publicly traded on stock markets designed for investors who don’t have the capacity to hold many stocks but are interested in diversification within the pharmaceutical sector.

  • Lenvima Could Significantly Boost Merck’s Revenue Growth
    Market Realist3 days ago

    Lenvima Could Significantly Boost Merck’s Revenue Growth

    In August, the FDA approved Merck’s (MRK) and Eisai’s Lenvima in the first-line setting for the treatment of individuals with unresectable hepatocellular carcinoma (or HCC). The FDA’s approval of Lenvima in the first-line setting for the treatment of HCC was based on data from the REFLECT trial.

  • Keytruda Could Boost Merck’s Revenue Growth in 2018 and Beyond
    Market Realist3 days ago

    Keytruda Could Boost Merck’s Revenue Growth in 2018 and Beyond

    On September 12, Merck (MRK) announced that the FDA accepted for review the company’s new supplemental Biologics License Application (or sBLA) for the label expansion of Keytruda. Merck seeks label expansion of Keytruda for approval as a monotherapy in the first-line setting. This treatment is intended for individuals with metastatic nonsquamous or squamous NSCLC (non-small cell lung cancer) with tumors expressing PD-L1 without EGFR or ALK genomic tumor abnormalities.

  • How Is Merck’s Keytruda Positioned in September?
    Market Realist3 days ago

    How Is Merck’s Keytruda Positioned in September?

    Merck’s (MRK) Keytruda has witnessed ~89% YoY (year-over-year) growth and generated second-quarter revenues of $1.7 billion. In the US market, Keytruda’s second-quarter revenues grew 73.0% to reach $959.0.0 million. In the international markets, Keytruda’s revenues increased ~118.0% YoY to reach $707.0.0 million.

  • Wall Street Analysts Are Mostly Positive on Merck in September
    Market Realist6 days ago

    Wall Street Analysts Are Mostly Positive on Merck in September

    Merck (MRK) recently announced that its pivotal Phase 3 trial that evaluated Zerbaxa met its primary endpoint. Zerbaxa is an investigational antibiotic for the treatment of adult individuals with ventilated hospital-acquired bacteria pneumonia or ventilator-associated bacterial pneumonia (or VABP). Zerbaxa demonstrated non-inferiority compared to meropenem.

  • Pharma Stock Roundup: AZN's Leukemia Drug Wins FDA Nod, MRK's Keytruda in Focus
    Zacks6 days ago

    Pharma Stock Roundup: AZN's Leukemia Drug Wins FDA Nod, MRK's Keytruda in Focus

    Label expansion of Merck's (MRK) Keytruda and FDA approval of AstraZeneca's (AZN) leukemia drug grab headlines this week

  • Are Options Traders Betting on a Big Move in Merck (MRK) Stock?
    Zacks6 days ago

    Are Options Traders Betting on a Big Move in Merck (MRK) Stock?

    Investors need to pay close attention to Merck (MRK) stock based on the movements in the options market lately.

  • Dow 30 Stock Roundup: Apple Unveils 3 New iPhones, Boeing Clinches $2.9B Deal
    Zacks6 days ago

    Dow 30 Stock Roundup: Apple Unveils 3 New iPhones, Boeing Clinches $2.9B Deal

    The index chalked up gains this week amid renewed hopes of trade talks between the United States and China.

  • Allergan Unveils Spotlyte, Its First Digital Ventures Launch
    Market Realist7 days ago

    Allergan Unveils Spotlyte, Its First Digital Ventures Launch

    On September 12, Allergan (AGN) announced the launch of Spotlyte, the first launch from Project Moonwalker, the Allergan-owned digital ventures unit. Spotlyte is an innovative digital hub designed to educate consumers about medical aesthetic treatments. The below chart lists key updates on Spotlyte. Spotlyte is the first venture from Project Moonwalker and is designed to educate consumers about medical aesthetics.

  • Merck Gets Priority Review for Yet Another Keytruda sBLA
    Zacks7 days ago

    Merck Gets Priority Review for Yet Another Keytruda sBLA

    Merck's (MRK) sBLA to include overall survival data from a key lung cancer study on Keytruda's label gets FDA's priority review. If approved, it will expand the eligible patient population.